| Literature DB >> 20874018 |
Craig Murdoch1, Kim J Reeves, Vanessa Hearnden, Helen Colley, Marzia Massignani, Irene Canton, Jeppe Madsen, Adam Blanazs, Steve P Armes, Andrew L Lewis, Sheila Macneil, Nicola J Brown, Martin H Thornhill, Giuseppe Battaglia.
Abstract
The prognosis for oral squamous cell carcinoma (OSCC) is not improving despite advances in surgical treatment. As with many cancers, there is a need to deliver therapeutic agents with greater efficiency into OSCC to improve treatment and patient outcome. The development of polymersomes offers a novel way to deliver therapy directly into tumor cells. Here we examined the internalization and biodistribution of two different fluorescently labeled polymersome formulations; polyethylene oxide (PEO)-poly 2-(diisopropylamino)ethyl methacrylate (PDPA) and poly 2-(methacryloyloxy)ethyl phosphorylcholine (PMPC)-PDPA, into SCC4 OSCC cells in vitro and in vivo. In vitro SCC4 monolayers internalized PMPC-PDPA and PEO-PDPA at similar rates. However, in vivo PMPC-PDPA polymersomes penetrated deeper and were more widely dispersed in SCC4 tumors than PEO-PDPA polymersomes. In the liver and spleen PMPC-PDPA mainly accumulated in tissue macrophages. However, in tumors PMPC-PDPA was found extensively in the nucleus and cytoplasm of tumor cells as well as in tumor-associated macrophages. Use of PMPC-PDPA polymersomes may enhance polymersome-mediated antitumor therapy.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20874018 DOI: 10.2217/nnm.10.97
Source DB: PubMed Journal: Nanomedicine (Lond) ISSN: 1743-5889 Impact factor: 5.307